MariMed: 213% YoY Increase In Q3 Adjusted EBITDA, Reaffirms Full-Year Revenue Guidance Of $118M
Portfolio Pulse from Jelena Martinovic
MariMed, Inc. (OTCQX:MRMD) reported significant growth in its Q3 financial results, with a 213% YoY increase in adjusted EBITDA and a 147% increase in revenue. The company reaffirmed its full-year revenue guidance of $118M and adjusted EBITDA of $42M. Operational highlights include substantial growth in revenue from retail dispensary operations and wholesale sales of cannabis products. Despite a 7.45% decrease in share price to $0.87, the company remains optimistic about meeting its full-year financial targets.
November 16, 2021 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
MariMed reported a 213% YoY increase in Q3 adjusted EBITDA and a 147% increase in revenue, reaffirming its $118M revenue guidance for 2021. Despite these strong results, shares dropped 7.45% to $0.87.
The significant YoY growth in adjusted EBITDA and revenue indicates strong operational performance and financial health. However, the short-term impact on the stock price is neutral due to the 7.45% decrease in share price following the announcement. This suggests that while the financial results are strong, market reactions or other external factors may be influencing the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100